BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 12845514)

  • 21. Management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day highly or moderately emetogenic chemotherapy: role of transdermal granisetron.
    Coluzzi F; Mattia C
    Future Oncol; 2016 Aug; 12(16):1865-76. PubMed ID: 27184113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative study of administration methods of granisetron injection used to treat nausea/vomiting induced by cancer chemotherapy without cisplatin in tumors of hematopoietic organs. Keihanshin Study Group of Hematological Malignancies.
    Tatsumi N; Masaoka T
    Cancer Chemother Pharmacol; 1999; 43(5):379-84. PubMed ID: 10100592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial.
    Yonemura M; Katsumata N; Hashimoto H; Satake S; Kaneko M; Kobayashi Y; Takashima A; Kato Y; Takeuchi M; Fujiwara Y; Yamamoto H; Hojo T
    Jpn J Clin Oncol; 2009 Jul; 39(7):443-8. PubMed ID: 19395466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Granisetron: relating pharmacology to clinical efficacy.
    Blower PR
    Support Care Cancer; 2003 Feb; 11(2):93-100. PubMed ID: 12560937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
    Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
    J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study.
    Tan M; Xu R; Seth R
    Curr Med Res Opin; 2004 Jun; 20(6):879-82. PubMed ID: 15200746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison of antiemetic efficacy of granisetron as premedication versus combination therapy of granisetron].
    Ikeda H; Koshiba R
    Gan To Kagaku Ryoho; 1998 Oct; 25(12):1947-53. PubMed ID: 9797818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical evaluation of 2 mg granisetron tablet for nausea and vomiting induced by anticancer drugs including cisplatin].
    Takada M; Furuse K; Fukuoka M; Kawahara M; Negoro S; Kusunoki Y; Ogawara M; Furue H
    Gan To Kagaku Ryoho; 1997 Jun; 24(8):987-94. PubMed ID: 9212809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
    Hsu ES
    Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical evaluation of granisetron as an inhibitor of nausea and vomiting induced by oral anticancer drugs.
    Togo S; Akiyama H; Yamaguchi S; Ichikawa Y; Ike H; Shimada H
    Oncol Rep; 2002; 9(2):277-82. PubMed ID: 11836592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutic potential of Granisetron (Kitryl) for the prevention of nausea and vomiting induced by cytostatic drugs].
    Gershanovich ML; Beresneva IA
    Vopr Onkol; 1998; 44(2):225-8. PubMed ID: 9615833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of oral granisetron versus i.v. granisetron in patients undergoing peripheral blood progenitor cell and bone marrow transplantation.
    Abang AM; Takemoto MH; Pham T; Mandanas RA; Roy V; Selby GB; Carter TH
    Anticancer Drugs; 2000 Feb; 11(2):137-42. PubMed ID: 10789597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
    Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K
    Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparison of clinical effects between granisetron alone and combination of granisetron and methylprednisolone against the nausea and vomiting induced by CDDP chemotherapy--comparative study by the cross-over trial. University of Tsukuba Antiemetics Study Group].
    Uchida K; Akaza H; Shimazui T; Kikuchi K; Manabe F; Iwasaki A; Ishikawa S; Noguchi R; Otani M; Hattori K; Kondo F; Nishijima Y; Sato K; Koiso K; Hinotsu S
    Gan To Kagaku Ryoho; 1996 Jan; 23(1):81-6. PubMed ID: 8546475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5-HT(3) regimen and literature review.
    Perez EA; Tiemeier T; Solberg LA
    Support Care Cancer; 1999 Nov; 7(6):413-24. PubMed ID: 10541984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study.
    Okamoto S; Takahashi S; Tanosaki R; Sakamaki H; Onozawa Y; Oh H; Miyawaki S; Kimura Y; Toyama K; Ikeda Y; Asano S
    Bone Marrow Transplant; 1996 May; 17(5):679-83. PubMed ID: 8733681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Granisetron, a antiemetic for treatment of cytostatic drug-induced vomiting: results of a practice-oriented study].
    Golaszewski T; Kölbl H; Lahousen M; Staab HJ
    Wien Klin Wochenschr; 1995; 107(20):613-21. PubMed ID: 7502509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting.
    Jordan K; Grothey A; Kegel T; Fibich C; Schöbert C
    Onkologie; 2005 Feb; 28(2):88-92. PubMed ID: 15662112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.